tirzepatide chile Los adultos con obesidad que usan tirzepatida mantienen una pérdida de peso «notable» a las 88 semanas – SOCHOB Son noticias muy alentadoras": Doctora

Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions

J.VizcarraJ

This page is presented for research and educational purposes only

Wegovy is the first FDA-approved weight loss medication